GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prestige Biologics Co Ltd (XKRX:334970) » Definitions » Research & Development

Prestige Biologics Co (XKRX:334970) Research & Development : ₩513 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Prestige Biologics Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Prestige Biologics Co's Research & Development for the three months ended in Dec. 2024 was ₩1,943 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was ₩513 Mil.

Prestige Biologics Co Research & Development Historical Data

The historical data trend for Prestige Biologics Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prestige Biologics Co Research & Development Chart

Prestige Biologics Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Jun23 Jun24
Research & Development
Get a 7-Day Free Trial Premium Member Only 18,363.95 25,097.18 30,969.92 17,385.03 9,300.85

Prestige Biologics Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8,168.91 4,977.22 -7,124.91 717.53 1,943.15

Prestige Biologics Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩513 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prestige Biologics Co  (XKRX:334970) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Prestige Biologics Co Research & Development Related Terms

Thank you for viewing the detailed overview of Prestige Biologics Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Prestige Biologics Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prestige Biologics Co Ltd (XKRX:334970) » Definitions » Research & Development
Comparable Companies
XKRX:115180 XKRX:199800 XKRX:389650 XKRX:140610 XKRX:397030 XKRX:078160 XKRX:228760 XKRX:372320 XKRX:304360 XKRX:048870 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
197, Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Chungcheongbuk-do, Cheongju-si, KOR, 28161
Website
https://www.prestigebiologics.com
Prestige Biologics Co Ltd is a CDMO-dedicated company that provides solutions of development and manufacturing tasks throughout the stages from the research/development, engineering, clinical production, commercial production, clinical support, and IND & BLA filing of biopharmaceutical products. Its product candidate includes HD201 (Herceptin Biosimilar).

Prestige Biologics Co Headlines

No Headlines